Smear plus Detect-TB for a sensitive diagnosis of pulmonary tuberculosis: a cost-effectiveness analysis in an incarcerated population by unknown
RESEARCH ARTICLE Open Access
Smear plus Detect-TB for a sensitive diagnosis of
pulmonary tuberculosis: a cost-effectiveness
analysis in an incarcerated population
Karen Barros Schmid1, Luciene Scherer2, Regina Bones Barcellos1, Daniele Kuhleis3, Isaías Valente Prestes4,
Ricardo Ewbank Steffen5, Elis Regina Dalla Costa1 and Maria Lucia Rosa Rossetti1,2*
Abstract
Background: Prison conditions can favor the spread of tuberculosis (TB). This study aimed to evaluate in a Brazilian
prison: the performance and accuracy of smear, culture and Detect-TB; performance of smear plus culture and
smear plus Detect-TB, according to different TB prevalence rates; and the cost-effectiveness of these procedures for
pulmonary tuberculosis (PTB) diagnosis.
Methods: This paper describes a cost-effectiveness study. A decision analytic model was developed to estimate the
costs and cost-effectiveness of five routine diagnostic procedures for diagnosis of PTB using sputum specimens:
a) Smear alone, b) Culture alone, c) Detect-TB alone, d) Smear plus culture and e) Smear plus Detect-TB. The
cost-effectiveness ratio of costs were evaluated per correctly diagnosed TB case and all procedures costs were
attributed based on the procedure costs adopted by the Brazilian Public Health System.
Results: A total of 294 spontaneous sputum specimens from patients suspected of having TB were analyzed. The
sensibility and specificity were calculated to be 47% and 100% for smear; 93% and 100%, for culture; 74% and 95%,
for Detect-TB; 96% and 100%, for smear plus culture; and 86% and 95%, for smear plus Detect-TB. The negative and
positive predictive values for smear plus Detect-TB, according to different TB prevalence rates, ranged from 83 to
99% and 48 to 96%, respectively. In a cost-effectiveness analysis, smear was both less costly and less effective than
the other strategies. Culture and smear plus culture were more effective but more costly than the other strategies.
Smear plus Detect-TB was the most cost-effective method.
Conclusions: The Detect-TB evinced to be sensitive and effective for the PTB diagnosis when applied with smear
microscopy. Diagnostic methods should be improved to increase TB case detection. To support rational decisions
about the implementation of such techniques, cost-effectiveness studies are essential, including in prisons, which
are known for health care assessment problems.
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Background
In 2011, 5.8 million newly diagnosed cases were reported
to national TB control programs and the World Health
Organization (WHO). The prevalence of TB in prisons
has been reported to be up to 100 times higher than that
of the civilian population [1]. This problem is particularly
critical in countries of high and intermediate TB inci-
dence ranging from 0.2% in Europe to 1.9% in Eastern
Ethiopia [2–7]. Although underestimated, the average
incidence of TB in the penitentiary system of southern
Brazil in 2006 was 0.7% (725/100,000), 15 times the rate
of the general population (48/100,000), according to the
State Program of Tuberculosis Control [8]. In a Brazilian
study from 2012, the TB incidence was 55/1,900 (2,894/
100,000) inhabitants in prisons [7]. Prison conditions
can favor disease spread through overcrowding, poor
ventilation, malnutrition and the lack of medical care.
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Additionally, late diagnosis, inadequate treatment and re-
peated prison transfers promote the transmission of TB
infection. Prisons act as a reservoir for TB, carrying the
disease into the civilian community through staff, visitors
and inadequately treated former inmates [9].
The conventional technique of smear examination with
Ziehl-Neelsen (ZN) is widely recognized as inexpensive
and easy, but its low sensitivity is a major drawback [10–
12]. Although the culture technique has proven to be
much more sensitive, it is much more time consuming
and laborious. Culture, supported by microscopy, still re-
mains the “gold standard” for active TB diagnosis, espe-
cially in low-resource countries, where they are the only
methods available for confirming TB in patients with a
clinical presumption of active disease [13]. Our aim, there-
fore, is to examine the utility of a molecular method of TB
detection within an incarcerated population to find a more
rapid alternative that enhances the active search for re-
spiratory symptoms. Many prior studies have observed
that the routine clinical use of PCR may be difficult due to
its high cost, particularly if PCR is used alone. These stud-
ies also emphasize the importance of clinical utility and
cost-effectiveness as a basis for making the decision to use
this technique [9–15].
The Xpert MTB/RIF, a rapid molecular test that can
diagnose TB and rifampicin resistance within 100 mi-
nutes, is an impressive example of the diagnostic innova-
tions that are currently being implemented. From its
endorsement by the WHO in December 2010 to the end
of June 2012, 1.1 million tests had been purchased by 67
low- and middle-income countries; South Africa (37% of
purchased tests) is the leading adopter. A 41% price re-
duction (from US$ 16.86 to US$ 9.98) in August 2012
should accelerate uptake [14].
Molecular techniques have the potential to improve clin-
ical care by dramatically reducing the time required for de-
tection and may provide substantial savings in the overall
costs of patient care [15–17]. Studies using molecular
techniques can be performed to evaluate the impact of
costs and the cost-effectiveness of new technologies on the
health care system. These studies have shown the potential
of molecular tests to detect and control TB [18–22]. Eight
billion dollars per year are necessary for TB control in
low- and middle-income countries, resulting in a high
impact on the health care system budget [14]. Recently, a
new molecular commercial kit has been developed in
Brazil for rapid and sensitive pulmonary TB (PTB) diagno-
sis, Detect-TB (Labtest, MG, Brazil). Detect-TB is based
on colorimetric detection of amplified product of the
IS6110 region hybridized with specific probe fixed on mi-
croplate [23]. Previous study has shown sensitivity ranging
from 75 to 100%, and specificity from 98 to 100% [23].
Considering the innovations in diagnostics and the
paucity of reports on health care cost impacts from TB,
especially with respect to incarcerated populations, this is
the first Brazilian study conducted on this subject. Using
spontaneous sputum samples, the following parameters
were evaluated: a) The performance and accuracy of the
smear, culture and Detect-TB strategies; b) The perform-
ance of smear plus culture and smear plus Detect-TB
strategies, according to different TB prevalence rates; and
c) The cost-effectiveness of routine diagnostic procedures
for PTB diagnosis using sputum specimens.
Methods
Study desing
This is a cost-effectiveness study. The model A hypo-
thetical cohort of 1000 patients was defined by patients,
which were infected with HIV or not, admitted to a
Prison in the south region of Brazil.
Study location and population
All sputum specimens used in this study were obtained
from the incarcerated population of the Penitenciária
Estadual do Jacuí of Charqueadas, Rio Grande do Sul,
Brazil. All samples were obtained from another study
performed by our group, in which the TB prevalence
was 72/1,900 (4,960/100,000) [7].
Sample collection
From August 2007 to August 2008, the medical records of
patients were admitted to the ambulatory by a screening
questionnaire given to 1,900 prisoners [7]. A total of 390
specimens of spontaneous sputum from patients suspected
of having TB were eligible for inclusion in the present study.
The patients were attended in a clinic room, with a specific
area for the collection of this type of material. All sputum
samples were taken to the Centro de Desenvolvimento
Científico e Tecnológico (CDCT) of the Fundação Estadual
de Produção e Pesquisa em Saúde (FEPPS) for processing.
The inclusion criteria were: cough for more than three
weeks; a signed informed consent form; and completion
of a questionnaire. Each patient was included in the
study only once and contributed only one isolate.
Eligible medical records were those in which: a) Patients
were confirmed as having PTB and that were clinically no-
tified by SINAM (Information System on Diseases of
Compulsory Declaration in Brazil); b) Age > 18 years; and
c) Period of hospital stay of more than 1 week. The med-
ical records of patients who were discharged in less than
one week from the hospital were excluded from the study.
The medical records of patients with PTB admitted to
ambulatory were analyzed. Pulmonary tuberculosis pa-
tients carried out 4 smear tests, 4 chest radiographs, and
nursing and physician consultations during hospitalization;
we used these parameters to estimate the costs of inpatient
assistance in the ambulatory, following the Brazilian rec-
ommendations for treatment [24].
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Chest radiographs and physical examination was per-




All PTB suspects provided a single specimen. The sam-
ples (500 μL) were treated with 2% N-acetyl-L-cysteine
(500 μL)/1 M NaOH (500 μL). The specimens were tested
by the Ziehl-Neelsen method (ZN) using smear micros-
copy, cultured in Löwenstein Jensen and identified accord-
ing to previous descriptions [24]. Laboratory and tested
using the Ziehl- Neelsen method, by culturing in Lowentein
Jensen medium with identification performed according to
Kubica’s method and employing the following criteria for
reading and interpreting: a) No bacillus in 100 fields report
result as negative; b) 1 to 10 bacillus in 100 fields report re-
sult as the specific quantity found; c) 10 to 99 bacillus in
100 fields report result as positive (+); d) 1 to 10 bacillus in
the first 50 fields report result as positive (++); and e) More
than 10 bacillus in the first 20 fields report result as positive
(+++) [24]. The clinical outcome was chosen as the gold
standard.
Molecular testing
Laboratory technicians who conducted the molecular
testing were blinded to the bacteriology results. DNA ex-
traction, purification and amplification were performed
as described previously [23]. To prevent DNA contamin-
ation, strict room separation was used, including a work
flow from initiation of the PCR to hybridization.
Briefly, Mycobacterium tuberculosis (MTB)-complex
DNA was amplified using biotinylated primers targeting the
IS6110 fragment. These amplified products were reverse-
hybridized on microwell plates (Nunc Immobilizer™ Amino
Surface, Nunc A/S, Roskilde, Denmark) to a fixed aminated
probe complementary to the internal region of the ampli-
fied IS6110 fragment. The hybridization signal was detected
by colorimetry using the streptavidin-peroxidase/TMB sys-
tem and measured using a spectophotometer with a 450/
620 nm filter. The absorbance of the negative control was
subtracted from the results, as recommended by Detect-TB
(Nunc Tech Note, 1999a, Nunc Tech Note, 1999b). All
samples with readings above 0.275 were considered positive
for MTB complex DNA [23].
Ethics
This study was approved by the Ethical Committee of
Fundação Estadual de Produção e Pesquisa em Saúde of
Rio Grande do Sul (FEPPS-RS) (410528/2006-4).
TB case definition
Pulmonary tuberculosis cases were defined as those with
a positive culture for MTB in the respiratory specimen
or those with positive clinical outcome (clinical and
radiological improvement after six months of solely anti-
TB treatment, as judged by three different chest phy-
sicians, who were not involved in this study, in a blinded
review) [25]. Negative PTB patients were considered
whose smear and culture for MTB were negative or who
did not show chest radiographic changes after six
months of follow-up. The gold-standard criteria for PTB
final diagnosis included all PTB cases, regardless of
whether they were confirmed by culture. Thus, the clin-
ical outcome was considered the gold standard.
Performance and accuracy analysis
The epidemiological and laboratory data were entered
into a computer database and analyzed with appropriate
statistical software (SPSS version 16.0).
The endpoints were sensitivity (SE), specificity (SP), and
the predictive negative and positive values (NPV, PPV) for
detection in suspected PTB patients. For MTB DNA de-
tection, the analysis of Detect-TB SE, SP, NPV and PPV
were performed on a per-study-subject basis, using the
diagnosis of PTB (defined above) as a reference standard.
Additionally, test performances of smear plus Detect-TB
or culture as a diagnostic test were calculated using spe-
cific formulas: SE of smear plus Detect-TB or culture: SE
smear + SE (Detect-TB or culture – (SE smear X SE (De-
tect-TB or culture), and predictive values (PV) for differ-
ent prevalence rates, according to the literature [26].
Costs
The cost components for each procedure included the
costs incurred by the patient, laboratory costs, drugs,
consumables and equipment costs. The number and
level of staff screening for TB in the hospital were con-
sidered to be the same for all strategies. Clinical, radio-
logical and laboratory staff costs were calculated from
the salary base of Rio Grande do Sul State of Brazil. For
each procedure, the costs were attributed based on the
procedure costs adopted by the Brazilian Public Health
System. For Detect-TB, the capital costs included the
cost of the thermocycler, microplate reader and centri-
fuge. Running costs (material costs used for each 1,000
tests evaluated) included all laboratory materials used in
the procedures.
All costs were expressed in US$, using an exchange
rate of US$ 1 = 3 R$ (Brazilian Real), by the procedure
described by Scherer [20]. To estimate the values spent
by the public health system of Brazil for the monitoring
and control of TB in a hospital and ambulatory unit, we
simulated two different scenarios: a) TB cases diagnosed
in hospital wards (inpatients) and b) TB cases diagnosed
in outpatient environment (outpatients). Therefore, to
calculate the total treatment cost, the treatment of inpa-
tients and outpatients were evaluated.
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The number of days considered when calculating the
costs related to the treatment of inpatients were consid-
ered the same as the days spent on each laboratory pro-
cedure. It was hypothesized that the time to detect MTB
in sputum culture from patients with PTB would be a bet-
ter indicator of the duration of hospitalization [27]. This
cohort is the same as that in previous publication from
our group [20].
Cost-effectiveness
A decision analytic model was developed using the
Treeage Pro software®2009 to estimate the costs and cost-
effectiveness of five routine diagnostic procedures for
diagnosis of PTB using sputum specimens: a) Smear alone,
b) Culture alone, c) Detect-TB alone, d) Smear plus cul-
ture and e) Smear plus Detect-TB.
The probabilities of events in the decision tree were de-
rived from: a) Published studies and b) The SE and SP of
the techniques. In this analysis, the tree was used to calcu-
late the expected value per correctly diagnosed TB case.
Table 1 shows the assumptions made in the construction
of the decision tree. We evaluated the cost-effectiveness
ratio of cost per correctly diagnosed TB case [28].
The SE analysis was performed to assess the effect of
the various parameters (TB prevalence, SE, SP, and vari-
able costs) on the outcomes.
Results
A total of 390 spontaneous sputum samples were evalu-
ated. Of these, 96 were excluded from analysis (5 showed
culture contamination, 84 had an insufficient amount for
molecular analysis, and 7 gave a reading in the gray zone).
Comparative performances of smear, culture and detect-
TB for PTB diagnosis
Of the 294 analyzed samples considering the clinical out-
come as the gold standard, 55 samples were defined as TB
cases and 239 non-TB cases. These results are displayed in
Table 2. Between the 55 defined as TB cases, 26 (47%)
showed positive results by smear, whereas 29 had false-
negative results; 51 (93%) showed positive results by the
culture, whereas 4 had false-negative results; 41 (74%)
showed positive results by Detect-TB, whereas 14 (26%)
had negative readings (false-negative). Among the 239 nega-
tive samples, 227 had negative results using Detect-TB, and
12 had positive readings (false positive). After this analysis,
the SE and SP of Detect-TB were calculated at 74% (CI
95%: 68%–79%) and 95% (CI 95%: 92%–97%), respectively.
Table 1 Model parameter value and ranges
Model assumptions




Smear positive cases 26
Culture positive cases 51
Detect-TB positive cases 41
Smear and culture positive cases 53




Ambulatory TB prevalence 0.10 0.05 0.20
Hospitalization TB prevalence 0.30 0.25 0.35
Study TB prevalence 0.038 0.028 0.048
TB prevalence in RS (state in southern of
Brazil)
0.047 0.037 0.057
SE smear 0.47 0.37 0.57
SE culture 0.93 0.83 0.99
SE Detect-TB 0.74 0.64 0.84
SE smear plus culture 0.96 0.86 0.99
SE smear plus Detect-TB 0.86 0.76 0.96
Table 2 Performance of smear, culture and Detect-TB
compared to the gold standard
N = 294
TB N = 55 Non-TB N = 239
Smear Positive 26 0
Negative 29 239
SE (%) SP (%)
47 100
(CI 95%: 41%–52%) (CI 95%: 99%–100%)
Culture Positive 51 0
Negative 4 239
SE (%) SP (%)
93 100
(CI 95%: 89%–96%) (CI 95%: 99%–100%)
Detect-TB Positive 41 12
Negative 14 227
SE (%) SP (%)
74 95
(CI 95%: 68%–79%) (CI 95%: 92%–97%)
Smear plus culture
SE (%) SP (%)
96 100
(CI 95%: 93%–98%) (CI 95%: 99%–100%)
Smear plus Detect-TB
SE (%) SP (%)
86 95
(CI 95%: 81%–90%) (CI 95%: 92%–97%)
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Accuracy analysis and the areas of ROC curve of smear,
culture, and detect-TB of PTB patients
Among 294 patients with PTB suspects, the ROC ana-
lysis showed the areas of smear (0.736), culture (0.964)
and Detect-TB (0.848), respectively (Figure 1).
Costs
The median time to reveal the growth of MTB was
30 days (Interquartile Range [IQR] 30 to 45) for smear
and culture, and the median time for detection of MTB
by Detect-TB was 3.32 days (IQR 3.0 to 3.75) (p < 0.01).
This value was used as the standard at which release
from isolation could be permitted [29].
The times spent on each activity in the laboratory to
provide results were assumed to be 2 days for smear
plus Detect-TB and 30 days for smear plus culture. The
numbers of days used to calculate costs was the same as
those spent on each laboratory procedure. The numbers
of days used to calculate patient travel costs were as-
sumed to be 2 days for smear plus Detect-TB and 30 days
for smear plus culture. The total treatment costs in-
cluded the clinical officer (physician salary) and hospital
costs; medication costs (based on US$ 0.22/pill, using 3
pills per day over 180 days); hospital room costs (US$
4.16 per day); costs of clinical staff salary and clinical
consultations (US$ 2.52 per patient); and costs of clinical
nursing consultations (US$ 2.52 per patient). The out-
patient treatment costs were calculated assuming the
6-month regimen recommended by the National TB pro-
gram and included 6 smear tests, 6 chest radiographs, 6
nurse consultations and 2 physician consultations [30].
The inpatient treatment costs included the time of
hospitalization, considered to be the same as the culture
time (30 days); 4 smear tests; 4 chest radiographs and 30
nurse and physician consultations [30]. The staff salaries
for the physician, nurse and radiologist were considered to
be US$ 36,000 per year, and for the chest radiograph tech-
nician, the salary was US$ 12,000 per year. The monthly
workdays were considered 20 days for all staff. The days of
admission to the hospital were considered to be the same
number of days used on each laboratory activity. All
assessed costs reflect an estimate of the public health sys-
tem of Brazil’s expenses regarding the monitoring and
control of TB. The costs were expressed per 1,000 sus-
pects, according to the specific bibliographic references
for economic analyses, thus allowing the best decision for
investment to be made [28]. In Table 3, the costs and as-




A decision analytic model (Table 1) was developed using
the Treeage Pro software®2009 to estimate the cost-
effectiveness of five diagnostic procedures for the diagnosis
of PTB using sputum specimens: a) smear used alone; b)
culture used alone; c) Detect-TB used alone; d) smear plus
culture; and e) smear plus Detect-TB (Figure 2).
In the cost-effectiveness analysis shown in Figure 3, the
smear alone strategy dominated, as it was both less
Figure 1 Plot in the ROC space of accuracy estimates to each method and areas corresponding to 294 patients. (blue: smear; green: culture;
yellow: Detect-TB).
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expensive and less effective than the other strategies.
Detect-TB and smear plus Detect-TB were less costly and
also effective when compared with the other strategies.
In a cost-effectiveness analysis presented in Table 4,
the ICER (Incremental Cost-Effectiveness Ratio) corre-
sponds with the best value (i.e., lowest cost per unit of
additional effectiveness). Smear plus Detect-TB showed
the lower ICER (0.061865) when compared to the others
strategies.
Discussion
The accuracy and cost-effectiveness of smear, culture
and Detect-TB were evaluated in a prison population
with a high prevalence of active PTB. We demonstrated
that smear plus Detect-TB was the most cost-effective
initial diagnostic test for active TB, indicating that
Detect-TB has great potential to be implemented under
routine diagnostic conditions. This is the first study in
Brazil that assessed the cost-effectiveness of a molecular
tool for TB diagnosis in a prison.
In PEJ, the TB prevalence was 72/1,900 (4,960/
100,000) between 2007 and 2008, which is at least 100
times higher than the rate found in the civilian popula-
tion [1]. In a Jail from Dourados city, Mato Grosso do
Sul – Brazil, 249 of 1,261 inmates participated in the
study for estimate active TB. The prevalence of the ac-
tive disease was 400 / 100,000 [31]. In one prison and
one jail in the city of Guarulhos, São Paulo – Brazil, a
total of 2,435 inmates were screened for TB. The coeffi-
cient of prevalence of TB by the smear microscopy was
289,3/100,000 and by the culture was 1,079.7/100,000
[32]. Studies from Sub-Saharan African prisons suggest
that 0.7% to 5.8% prisoners have undiagnosed active tu-
berculosis [33]. There is limited data on the prevalence
of TB from prisons and these findings emphasize the in-
creased risk of undetected TB in prisons.
A total of 294 patients with potential PTB were evalu-
ated by smear, culture and Detect-TB. These results
were compared to the clinical outcome, which was con-
sidered the gold standard. The SE and SP values were
47% and 100% for smear, 93% and 100% for culture, 74%
and 95% for Detect-TB, 96% and 100% for smear plus
culture, and 86% and 95%, for smear plus Detect-TB, re-
spectively. The overall SE and SP of Detect-TB were
similar to culture in the diagnosis of PTB.
In a previous study carried out by our group, the SE and
SP of Detect-TB using spontaneous sputum were 85% and
98%, respectively [23]. A study performed on hospitalized
patients in Uganda, in 2012, to diagnose the accuracy and
impact of Xpert MTB/RIF among high-risk TB suspects,
found a SE of 79% (CI 73%–84%), a SP of 96% (CI 92%–
98%), a negative predictive value of 79% and a positive
predictive value of 95% [34]. These data are in agreement
with the findings obtained using Detect-TB. In another
study on the diagnostic accuracy of Xpert MTB/RIF in
HIV-infected patients, the SE was 91.7% (CI 64.6%–
98.5%), the SP was 99.3% (CI 96.3%–99.9%), the NPV was
Table 3 Unit costs (in US$) of 1000 TB suspects screening,
comparing smear plus culture and smear plus Detect-TB





Total cases TB 53 48
A health service costs (in US$)
Laboratory costsa
Laboratory costs 3,283 13,067
Investment costs 123 194
Running costs 12,333 12,833
Treatment costs (outpatients) 3,819 337
Treatment costs (inpatients) 3,690 328
Treatment costs (outpatients/inpatients) 7,508 665
Diagnostic service costs per daya
Staff costs per activity-based costing 1,158 77
B1. Patient cost (outpatient)d
Travel 24 2
Food 100 7
Income loss 175 12
B2. Patient cost (inpatient)d
Travel 0 0
Food 0 0
Income loss 175 12
Total patient costs 299,000 19,933
Total health service costs 1,180.748 103,926
Total screening costs in 1000 TB cases 1,479.748 123,859
aFor each procedure, costs were attributed based on procedure costs of the
Brazilian public health system (US$ 1.4 for smear and US$ 1.9 for culture) and
from CDCT/FEPPS (US$ 11.7 for Detect-TB), assuming investment laboratory
equipment for 5 years; bStaff salary was considered; for laboratory technician, US
$2,860 per year; for Laboratory technologist, US$6,400 per year. Staff costs in the
laboratory were based on proportional days spent on each laboratory procedure;
Staff salary was considered for clinical physician, nurse and radiologist; US$6,400
per year; for the X-RAY technician, salary was US$2,860 per year. cThe days of
hospitalization were considered as the same as the days spent on each laboratory
procedure. The time spent on each laboratory procedure until access to the result
of the laboratory technique was assumed to be 2 days for smear plus Detect-TB
and 30 days for smear plus culture. Total treatment included clinical officer and
hospital costs, assuming US$ 0.22 cost per pill, using 3 pills for day, during
180 days; hospital room costs, US$ 4.16/day; costs of salary of staff clinical; clinical
consultation cost, US$2.52 per patient; clinical nursing consultation, US$2.52 per
patient. Assuming that during the treatment of hospitalized patients (4 months) 4
smear and 4 chest radiograph were performed, and during the treatment of out-
patients (6 months) 6 smear and 6 chest radiograph were performed, following
the Brazilian recommendations for treatment (Tuberculose 2004); dTravel for
smear strategies was considered as 30 days for smear plus culture strategy; and
2 days for smear plus Detect- TB. Food and income loss for smear strategies was
considered as 30 days for smear plus culture strategy; and 2 days for smear plus
Detect- TB. The health service costs analysis was based on processing 50 smear
slides, 86 samples for each PCR (Detect- TB) and 14 cultures per day. Smear plus
culture and Detect- TB were performed by two trained staff, respectively. Costs of
chest physicians were considered the same for all strategies. Running costs were
calculated from investments required to examine 1000 smears.
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99.3%, and the PPV was 91.7%. This finding reinforces the
fact that Detect-TB is comparable with commercially
available kits. The SE, SP, NPV and PPV for Detect-TB are
particularly interesting because the study population is
from a prison, where the HIV positive rates are well-
known to be 5- to 7-times higher than in the general
population [35]. In the present study, it was not possible
to assess the HIV rate. Any declared HIV status could
have been included, but was not considered in this ana-
lysis. The use of molecular methods is particularly relevant
in HIV-positive patients due to its paucibacillary nature
and the difficulties in obtaining a satisfactory molecular
test performance [36]. As the HIV status was obtained by
declaration, sample stratification for statistical analyses
was not performed. This can be considered an intrinsic
study limitation. Furthermore, using smear plus Detect-
TB as a TB diagnostic tool allowed for an earlier diagnos-
tic assessment, many days in advance, than smear plus
culture. Additionally, the difference between the accuracy
of smear plus culture and smear plus Detect-TB was small
(Table 2). The accuracy analysis was demonstrated by the
ROC curve analysis, which mapped the areas of smear
(0.736), culture (0.964) and Detect-TB (0.848), and showed
that culture is the most accurate method for TB diagnosis
Figure 2 Tree decision model. Values = cost (US$) per detected case.
Figure 3 Cost-effectiveness of five strategies for TB diagnosis. (smear; culture; Detect-TB; smear plus Detect-TB; and smear plus culture).
Cost-effectiveness = cost per detected case; cost = US$; effectiveness = detected case.
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when analyzed independently. Through the simulation of
NPV and PPV considering different TB prevalence rates
(Table 5), the smear plus Detect-TB NPV ranged from 83
to 99%, whereas the PPV ranged from 48 to 96%. Thus,
high negative predictive values were observed with a TB
prevalence of 4.9-20%, confirming that the strategy of
using smear plus Detect-TB can be used to exclude TB
cases in PEJ population. In addition, a high PPV for
smear plus Detect-TB was observed, which was very
similar to that of smear plus culture, reinforcing its
good test performance, especially in high prevalence
sites.
In this study, we demonstrated that smear plus Detect-
TB provided more cost-effective results compared to
routine methodology (smear plus culture). Though costs
increase slightly, Detect-TB provides a more rapid
diagnosis. It is already known that smear has a reduced
SE, so it is necessary to use culture as a complementary
method. This study evaluated the use of Detect-TB as a
complementary method and showed great performance
(Figure 3). Importantly, among the 24 smear-negative
culture-positive samples, Detect-TB was able to identify
67% of them. This resulted in a gain using Detect-TB re-
gardless of the use of culture, which translates into an in-
crease in TB case detection, showing greater quickness
and efficiency. This is a very important issue in developing
countries, where TB is epidemic and scarce financial re-
sources are available to public health [18,37]. Early, accur-
ate treatment becomes essential because this is the trigger
point in the fight against resistance, and its spread in the
general community, particularly in Brazil, where there are
no visitor restrictions to prisoners and where weekly family
visits are not uncommon. In these types of sites, there is no
data on the performance and cost-effectiveness of molecu-
lar approaches. As for an intervention, the high cost of
PCR itself is often used as an argument not to introduce it.
However, its cost-effectiveness is a better argument for
making such a decision [9–15]. In a cost-effectiveness ana-
lysis, sometimes a strategy can be eliminated based on its
relative cost and effectiveness compared to another strat-
egy. Using such an approach, an option is said to be domi-
nated if both costs and effectiveness were more costly or
less effective than a select strategy compared with the
others, and in this case, the smear strategy is the most ef-
fective. According to the current data, the smear plus
Detect-TB was the most cost-effective compared with the
other strategies. The SE analysis indicated that significant
factors contributed to the cost of strategies, time perform-
ance and the Detect-TB cost. In cost-effectiveness studies
using indicators, such as the ICER, that describe the differ-
ence in cost, the difference in effectiveness between two
scenarios is critical. The ICER is often reported as the cost
per DALY (Disability-Adjusted Life Year Averted) and is al-
ways compared against a reference strategy [20]. In the
present study, the ICER was reported as the cost per case
detected and was US$ 0.061865 for the strategy smear plus
Detect-TB. Evaluations of the cost-effectiveness of new
diagnostic tests for TB in countries with resource con-
straints and high TB-HIV prevalence are still scarce, and
Table 4 Cost-effectivenes of five strategies for TB diagnosis (smear; culture; Detect-TB; smear plus Detect-TB; and
smear plus culture)
Strategy Cost per patient (US$) Incremental cost (US$) Effectiveness (Detected case) C/E Ratio ICER
Smear 0.224327 26 0.008628
Culture 19.27714 2.12365 51 0.377983 (Dominated)
Detect-TB 1.59707 0.01171 41 0.038953 (Dominated)
Smear plus Detect-TB 1.585356 1.36103 48 0.033028 0.06186
Smear plus culture 17.15348 15.5681 53 0.323651 3.11362
Table 5 Simulation of positive and negative predictive
values according to different TB prevalence rates
Simulated prevalence rates N = 294
TB N = 55 NTB N = 239
PPV (%) NPV (%)
4.9% Smear plus culture 50 99
Smear plus Detect-TB 48 99
PPV (%) NPV (%)
10% Smear plus culture 68 99
Smear plus Detect-TB 66 98
PPV (%) NPV (%)
20% Smear plus culture 82 99
Smear plus Detect-TB 81 97
PPV (%) NPV (%)
30% Smear plus culture 89 98
Smear plus Detect-TB 88 94
PPV (%) NPV (%)
40% Smear plus culture 92 97
Smear plus Detect-TB 92 92
PPV (%) NPV (%)
60% Smear plus culture 96 94
Smear plus Detect-TB 96 83
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much remains to be studied. In a recent study, the ICER of
four hypothetical strategies for the diagnosis of TB (smear,
a new test for the diagnosis, smear associated with the new
test and smear associated with culture) were evaluated in
Brazil, Kenya and South Africa. The smear was more cost-
effective (Increment Cost per DALY), with US$ 86 [South
Africa], US$ 131 [Brazil], and US$ 38 (Kenya], than the
new hypothetical test, which showed a SE of 70% and a SP
of 95%, and the costs of US$ 20 per test (US$ 198 [South
Africa], US$ 275 [Brazil] and US$ 84 [Kenya]) [21].
The evaluation of the cost-effectiveness of molecular
tests has emphasized the evaluation of commercial and in
house testing. In a study conducted in 2005, the cost per
correctly diagnosed case was US$ 41 for smear and US$
67 for PCR (AMPLICOR). When treatment costs were in-
cluded, PCR (AMPLICOR) was more cost-effective, US$
382 versus US$ 412. In a recent study, the cost per cor-
rectly diagnosed case was US$ 50.773 for smear and cul-
ture and US$ 13.749 for smear and PCR dot-blot. The
smear associated with PCR dot-blot was more cost-
effective than smear-associated culture [20]. In the present
study, the cost per correctly diagnosed case was US$
29.014 for smear plus culture and US$ 3.021 for smear
plus Detect-TB. Whereas the performance of a molecular
test to diagnose PTB may be linked directly to the detec-
tion method [16,17], in this study, the method of detection
showed a reduction of 78% in the costs of the smear plus
DETECT-TB strategy when compared to the use of smear
associated with PCR-dot-blot in a previous study from our
group.
The limitations of the study were: a) Pulmonary tuber-
culosis cases were defined as those with a positive culture
for MTB in the respiratory specimen or those with clinical
and radiological improvement after six months of solely
anti-TB treatment; b) Stratification of different diagnostic
strategy results by HIV status was not performed; c) Mor-
tality was not measured for either strategy; d) For treat-
ment cost analysis, costs related to the following were not
included: I) The inadequate use of non anti-TB drugs; II)
The adverse effects of the inadequate use of anti-TB drugs
for non-TB subjects; III) The occurrence of drug-resistant
TB (MDR-TB and non –MDR); IV) The delay in treat-
ment and impairment of other physical conditions caused
by adverse effects of drugs; V) The occurrence of new
cases and previously treated cases; and VI) The incidence
of male or female patients; e) Patient isolation use or con-
tact investigation was not included in the analysis; f ) In
the cost-effectiveness model analysis were not used a
Markov analysis because time was not determinant of
outcome in our study. Our outcome was case-detected;
g) We did not use the QALY as an indicator of effective-
ness because we use TB cases diagnosed by the technique
according established model; and h) These results are sig-
nificant for evaluation during the current global phase of
worldwide economic crisis, particularly in a country such
as Brazil with a high prevalence of TB.
Conclusions
Although some studies have demonstrated that PCR is
more sensitive and specific, but also more costly, than
other routine procedures [38], Detect-TB proved to be
the most cost-effective procedure for diagnosis in this
study, when used in combination with smear.
Diagnostic tests and procedures should be improved
to increase the detection of TB cases. In addition to im-
proving detection using procedures based on smear, al-
ternative techniques should be considered. To allow
rational decisions concerning the implementation of
such techniques, cost-effectiveness studies are essential,
including for prisons, which are crowded sites fraught
with health care assessment problems. Such studies elu-
cidate the composition of the different cost components,
which should be evaluated from the perspective of the
patient or health services.
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